Cell death is a vital process that occurs in billions of cells in the human body every day. This
process helps maintain tissue homeostasis, supports recovery from acute injury, deals with …

Introduction: Cardiovascular (CV) mortality is increased in patients with ankylosing
spondylitis (AS), but little is known about CV morbidity beyond the fact that they have a two …

Secukinumab, a selective interleukin (IL)-17A inhibitor, is approved for use in adult and
paediatric psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial …

Objectives To provide an integrated analysis of major adverse cardiovascular events
(MACEs) and events of venous thromboembolism (VTE) and associated risk factors across …

Abstract Objective Several biological DMARDs (bDMARDs) have demonstrated anti-
inflammatory effects in PsA. However, their comparative cardiovascular safety profiles …

Purpose JAK-inhibitors (JAK-i) might be associated with venous (VTE) and arterial
thromboembolic events (ATE). To evaluate the association between JAK-i and the risk of …

This narrative review provides a comprehensive examination of the complex interplay
between inflammatory arthritis (IA) and cardiovascular pathology. It particularly illuminates …

Objectives The objectives of this study were to describe the incidence of major adverse
cardiovascular events (MACEs) in French patients newly benefiting from the French Long …

Introduction Ankylosing spondylitis (AS), and carriage of HLA-B27 gene in otherwise healthy
individuals, are reportedly associated with increased mortality. We evaluated this …

Increased risk of comorbidities has been reported in Rheumatic and Musculoskeletal
Diseases (RMD). We aimed to evaluate the prevalence and pattern of comorbidities in RMD …